2022 Annual Report

WE AIM TO END MELANOMA

WHATWEDO

We direct, manage and fund COLLABORATIVE RESEARCH INITIATIVES, on a national and global scale. Our initiatives are innovative. We ask the world?s leading melanoma researchers what they need? what?s missing in the fight? and listen when they respond.

We speak on behalf of melanoma patients and families through our work in LEGISLATION, POLICY, AND ADVOCACY. The invited presence of our staff on numerous boards and committees that directly affect patients is one indication of our leadership in the world of melanoma.

The breadth, depth, and number of our EDUCATION AND SUPPORT resources for the melanoma community are second to none. Whether you?re a patient, survivor, caregiver, family member, nurse, physician, or researcher, we have so much to offer.

2022 was a year of growth for the AIM at Melanoma Foundation.

This annual report describes three notable successes in 2022 for AIM at Melanoma? one from each of the areas of our mission. Each of these accomplishments demonstrates the growth, expansion, or increase of one of our already successful programs.

You are the reason for our successes, and we are grateful for your support.

Samantha Guild, President AIM at Melanoma Foundation

2022

A Year To Rem em ber

AIM at Melanom a has so m any accom plishm ent s t o celebrat e

"Bystudyingprimarytissue, wehopeto find high riskfeaturesof tumors. We hopeto figureout which melanomaswill spread. Wehopeto knowwhich patientsto watch more carefullyand to scan regularly. Wehopeto figureout who will respond to which drugs. There isso much wedon? t know? and so much wecan find in fresh frozen primarytumor tissue."

Dr. Mohammed Kashani-Sabet, M.D., Director, Center for Melanoma Research and Treatment; Medical Director, Cancer Center, California Pacific Medica Center

THEINTERNATIONALMELANOMATISSUEBANKCONSORTIUM(IMTBC)

SUCCESS:

At t he end of 2022, w e had collect ed 119 fresh frozen prim ary t issues

All four U.S. sites collected tissue in 2022! At t he end of t he year, w e had banked a t ot al of 119 prim ary m elanom as, all fresh frozen, w it h depersonalized pat ient dat a and blood sam ples. Collection had slowed or stopped at all sites during the COVID years (2020 and 2021)so it was gratifying to ramp collection back up in 2022.

SUCCESS:

Expanding our global advocacy reach

AIM?s Melanoma International Patient Advocacy Coalition (MIPAC) and our general global reach have been growing and improving, especially in 2022. For example, we expanded our global outreach to Africa, starting communication and advocacy work with a doctor in Nigeria that will benefit melanoma patients in that country. This connection is the beginning of what we hope will be a growing relationship with Nigeria and other African countries.

Another example: Our President, Samantha Guild, spoke at Melanoma Bridge? an important global research meeting? in Naples, Italy. The fact that she spoke is not remarkable; what is worth noting isthat her topic focused on how advocates are critical partners in research? especially in clinical trials? and advocates do this work all over the globe. Her talk was so well received that she was invited to give it several more times to other audiences in 2023.

With Samantha in Naples was one of our advocates? Claudia Cidonio, from Italy, who is a member of MIPAC. MIPACis a program through which AIM supports international advocates who do critical work in their home countries/regions. Claudia also spoke at Bridge about her work, and her speech also captured the growth in AIM?s MIPACprogram.

AIM provides both funding and content for websites, social media campaigns, and traditional media campaigns. Many of AIM?s educational materials are translated for use in these countries/regions, including AIM?s website.

MIPACmembers and AIM leadership meet yearly, at the Post-Chicago Melanoma/Skin Cancer meeting held in Munich. This conference allows the advocates the opportunity to be updated on the ever-evolving melanoma landscape as well as to network with key opinion leaders and healthcare professionals.

The meeting, the funding, and the materials give the advocates the tools and resources to successfully advocate on behalf of their melanoma communities.

MIPACcountries/regions now number 11: Australia, Brazil, Canada, Eastern Europe, France, Israel, Italy, Latin America, Portugal, Spain, and the United Kingdom. As we alwayssay, Melanoma is a global disease, and it needs a global solution.

EDUCATIONANDSUPPORT

One of AIM at Melanoma?smost beloved staff membersis Melissa Wilson, PA-C,MPAS, Melanoma Lead with UPMCHillman Cancer Center. Me ssa leads AIM?s ?Ask a Medical Expert?program, which was created to help pat ents understand their melanoma diagnosis, its imp cations, and how to approach and navigate their situation. Melissa also hosts From the Clinicto theLiving Room,webinars that explore everything you need to know about me anoma.

SUCCESS:

A New Resource: Melanom a 101 Videos

In 2022, Mel ssa began offering a new program called Melanoma 101, which is a series of 5-10 minute whiteboard videos on var ous melanoma topics. As the name suggests, Melissa hosts the videossitting n front of a whiteboard,where she diagrams and illustrates different melanoma concepts,so patientsand their families can understand a topic by both seeing and hearing about t.

Melanoma 101 br ngs clarity to melanoma's complexity. It?s a program designed to help usall better understand the disease.

All of the Melanoma 101 whiteboard videos are available on YouTube. Here are some of the Melanoma 101 topics that were offered in 2022:

- How Do Skin MolesForm?

- How Melanoma Growsand Spreads

- What isa SkinBiopsy?

- TheABCDEsof Melanoma

Melanom a 101 videos had over 41,000 view s by t he end of 2022!

THANKYOU

AIM at Melanoma?s goal is to end this disease in our lifetime while improving the lives of those it affects, and we are able to pursue this goal because of our supporters?generosity. We are committed to sound financial practices, transparency, and accountability, all of which are critical to attracting and keeping the generous funding that allows us to fulfill our mission.

HOWAIMATMELANOMAUSESFUNDS

Thank you for your support and your trust.

Toget her, w e can end m elanom a.

HOWWILL2023 FINISH?

What w ill w e announce as accom plishm ent s in t he next annual report ?

- Exciting tissue bank progress

- AIM is working to help open up clinical trials outside the U.S.

- A significant increase in new and comprehensive content on our website

Head over to AIMatMelanoma.org for more!

In addition to our generous donors, thank you to our Board of Directors and our Advisory Board.